Nonhormonal treatment regimens improve survival in patients with metastatic breast cancer
Nonhormonal treatment regimens, including anthracycline-based regimens and taxanes, have improved overall survival in women with advanced (metastatic or recurrent inoperable) breast cancer over the last 35 years, according to a systematic review published December 9 in the Journal of the National Cancer Institute. Numerous regimens have been tested in advanced breast cancer. However, each of the trials has compared only a few regimens, making it difficult for researchers and clinicians to know the relative merit of the individual regimens.
To learn how regimens compare with one another, John P. A. Ioannidis, M.D., of the University of Ioannina School of Medicine in Greece and colleagues performed a meta-analysis of 128 clinical trials that included 148 comparisons between regimens and that enrolled 26,031 women with advanced breast cancer. The investigators used single-agent chemotherapy with old non-anthracycline drugs as the baseline for comparison within their meta-analysis.
The use of anthracycline regimens led to a 22 percent relative risk reduction in overall mortality as compared with older single agent chemotherapy. Single drug taxane treatment led to a similar relative risk reduction of 33 percent, while the combination of a taxane with capecitabine or gemcitabine led to a 51 percent relative risk reduction over the single agent chemotherapy. Most of the regimens appeared to have similar efficacy when used in women who had not been previously treated and in women who had had prior therapy.
"Our meta-analysis quantifies the progress achieved in the treatment of advanced breast cancer with nonhormonal systemic treatment in the last 35 years. Several regimens have shown effectiveness, and for some of them, the treatment effects are practically indistinguishable in magnitude," the authors write. "Given that subsequent lines of treatment can confer similar relative benefits as the first-line setting, one can exploit the survival benefits conferred by several effective regimens used in sequential fashion."
In an accompanying editorial, Philippe Bedard, M.D., and Martine Piccart-Gebhart, M.D., Ph.D., of the Jules Bordet Institute in Brussels, Belgium, note that there has been no consensus regarding the best dosage, timing, sequence or combination of therapies for the treatment of metastatic breast cancer because standard comparators have not been available. Therefore, the work of Ioannidis and colleagues is important.
Given the investigators' finding that many of the regimens have similar relative effectiveness in previously-untreated and -treated patients, no clear order of use appears from the meta-analysis. Other considerations, such as toxicity, will continue to help drive the choice of regimen for individual therapy, the editorialists argue.
"Although this network meta-analysis is unlikely to alter routine clinical practice, it provides a solid evidence-based foundation to support the observation that the survival of women diagnosed with advanced breast cancer has improved because of more active systemic chemotherapy and targeted therapy," the editorialists write. "This should provide hope to patients, investigators, industrial sponsors, and regulatory agencies alike that well-designed clinical trials with novel systemic therapies can further alter the natural history of this devastating disease."
- Survival in metastatic breast cancer patients is improving: targeted therapies have contributedFri, 26 Mar 2010, 8:32:22 EDT
- Cetuximab did not add significant benefit to NORDIC FLOX regimen in first line treatment of mCRCTue, 12 Oct 2010, 10:36:14 EDT
- New studies on surgical options in inherited breast cancer show drastic treatment is not always bestFri, 26 Mar 2010, 8:32:19 EDT
- Adding taxotere to chemotherapy regimen improves survival in early breast cancerMon, 15 Sep 2008, 20:29:21 EDT
- New treatment regimen shows clinical benefit in advanced colon cancerWed, 18 May 2011, 19:02:38 EDT
Articles on the same topic
- Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 targetFri, 12 Dec 2008, 13:15:31 EST
- Early stage, HER2-positive breast cancer patients at increased risk of recurrenceFri, 12 Dec 2008, 13:15:26 EST
- Estrogen pills can benefit women with metastatic breast cancerThu, 11 Dec 2008, 11:59:33 EST
- Marital problems lead to poorer outcomes for breast cancer patientsMon, 8 Dec 2008, 13:58:38 EST
- Confusing risk information may lead breast cancer patients to make poor treatment choicesMon, 8 Dec 2008, 13:50:45 EST
- Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genesThu, 4 Dec 2008, 17:18:46 EST
- HER2 levels may aid in treatment selection for metastatic breast cancerTue, 2 Dec 2008, 10:49:47 EST
- European ancestry increases breast cancer risk among LatinasMon, 1 Dec 2008, 7:15:17 EST
- Early stage, HER2-positive breast cancer patients at increased risk of recurrencefrom PhysorgFri, 12 Dec 2008, 15:07:34 EST
- Researcher finds most triple-negative breast cancers express muc-1 targetfrom PhysorgFri, 12 Dec 2008, 15:07:32 EST
- Early Stage, HER2-positive Breast Cancer Patients At Increased Risk Of Recurrencefrom Science DailyFri, 12 Dec 2008, 13:28:18 EST
- Oestrogen pills can benefit women with metastatic breast cancerfrom Science CentricFri, 12 Dec 2008, 5:08:08 EST
- Estrogen pills can benefit women with metastatic breast cancerfrom PhysorgThu, 11 Dec 2008, 15:02:09 EST
- Breast Cancer Treatment Offers Better Outcome To Women With Implantsfrom Science DailyWed, 10 Dec 2008, 21:15:47 EST
- Marital Problems Lead To Poorer Outcomes For Breast Cancer Patientsfrom Science DailyWed, 10 Dec 2008, 9:35:26 EST
- Breast Cancer Treatment Spares Implantsfrom Live ScienceWed, 10 Dec 2008, 9:08:18 EST
- Nonhormonal treatment regimens improve survival in patients with metastatic breast cancerfrom Science CentricWed, 10 Dec 2008, 6:21:39 EST
- Nonhormonal treatment regimens improve survival in patients with metastatic breast cancerfrom PhysorgTue, 9 Dec 2008, 18:21:09 EST
- Marital problems lead to poorer outcomes for breast cancer patientsfrom Science CentricTue, 9 Dec 2008, 8:00:06 EST
- Confusing risk information may lead breast cancer patients to make poor treatment choicesfrom Science CentricTue, 9 Dec 2008, 6:03:44 EST
- Confusing risk information may lead breast cancer patients to make poor treatment choicesfrom PhysorgMon, 8 Dec 2008, 14:21:56 EST
- Marital problems lead to poorer outcomes for breast cancer patientsfrom PhysorgMon, 8 Dec 2008, 13:56:35 EST
- European Ancestry Increases Breast Cancer Risk Among Latinasfrom Science DailySun, 7 Dec 2008, 0:35:28 EST
- Few Ontario women with invasive ovarian cancer referred for genetic testing of breast cancer genesfrom Science CentricThu, 4 Dec 2008, 19:30:45 EST
- HER2 levels may aid in treatment selection for metastatic breast cancerfrom Science CentricWed, 3 Dec 2008, 4:11:20 EST
- HER2 levels may aid in treatment selection for metastatic breast cancerfrom PhysorgTue, 2 Dec 2008, 12:49:23 EST
- European ancestry increases breast cancer risk among Latinasfrom Science CentricMon, 1 Dec 2008, 11:49:25 EST
- European ancestry increases breast cancer risk among Latinasfrom PhysorgMon, 1 Dec 2008, 7:14:19 EST
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Researchers reveal model of Sun's magnetic field
- 2 miniature spider species discovered in Giant Panda Sanctuaries of China
- The Norway spruce genome sequenced
- UCLA life scientists present new insights on climate change and species interactions
- Baby's life saved with groundbreaking 3-D printed device that restored his breathing
- Allosaurus fed more like a falcon than a crocodile, new study finds
- Invasive crazy ants are displacing fire ants in areas throughout southeastern US
- Beautiful 'flowers' self-assemble in a beaker
- Scientific insurgents say 'Journal Impact Factors' distort science
- GPS solution provides 3-minute tsunami alerts